1. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma
   Heike Niessner et al, 2023, Cancers CrossRef
2. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
   Francisco Meraz-Torres et al, 2024, Journal of Experimental & Clinical Cancer Research CrossRef
3. Primary Undifferentiated/Dedifferentiated Cutaneous Melanomas—A Review on Histological, Immunohistochemical, and Molecular Features with Emphasis on Prognosis and Treatment
   Dana Antonia Țăpoi et al, 2023, International Journal of Molecular Sciences CrossRef
4. Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta‐analysis
   Allan Vinícius Martins‐de‐Barros et al, 2023, Journal of Oral Pathology & Medicine CrossRef
5. Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma
   Lucas Schneider et al, 2023, European Journal of Cancer CrossRef
6. Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
   Adriana Celesia et al, 2023, International Journal of Molecular Sciences CrossRef
7. Incidence of BRAF mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population
   Oleksandr Dudin et al, 2023, Melanoma Management CrossRef
8. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
   Xiaoting Wei et al, 2024, European Journal of Cancer CrossRef
9. Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR
   Elena-Georgiana Dobre et al, 2024, International Journal of Molecular Sciences CrossRef